Navigation Links
GlaxoSmithKline Consumer Healthcare to Reach 85 Percent of the World's Smokers with Quit Aids
Date:3/9/2009

file of therapeutic nicotine products when used as directed(4). Therapeutic nicotine is recommended as a first-line treatment for smoking addiction in United States, United Kingdom and World Health Organization (WHO) guidelines(2,3,5). To date, GSK's therapeutic nicotine has helped more than six million people around the world quit smoking, and as a result, has greatly reduced their exposure to the risks of cancer and other smoking-related diseases(6).

These products are designed specifically to break the addiction cycle by offering a gradual, controlled delivery of nicotine to the body, helping to relieve withdrawal symptoms.

About GlaxoSmithKline Consumer Healthcare

GlaxoSmithKline Consumer Healthcare is one of the world's largest over-the-counter consumer healthcare products companies. Its more than 30 well-known brands include the leading smoking cessation products, NicoDerm(R) CQ and Commit(R), NiQuitin and Nicabate, as well as many medicine cabinet staples such as Aquafresh(R), Panadol(R), Crocin(R), Horlicks(R) and Sensodyne(R). GlaxoSmithKline Consumer Healthcare continues to develop innovative products to help all smokers find their best support system and achieve their goal of being cigarette free.

About GlaxoSmithKline

GlaxoSmithKline is one of the world's leading research-based pharmaceutical and consumer healthcare companies. GlaxoSmithKline is committed to improving the quality of human life by enabling people to do more, feel better and live longer.

(1) Jha, et al; A Nationally Representative Case - Control Study of Smoking and Death in India; NEJM, 2008

(2) World Health Organization. WHO Report on the Global Tobacco Epidemic, 2008. Geneva: World Health Organization; 2008 [cited 2008 Mar 21]. Available from: http://www.who.int/tobacco/mpower/en/

(3) Fiore MC, Jaen CR, Baker TB, e
'/>"/>

SOURCE GlaxoSmithKline Consumer Healthcare
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. GlaxoSmithKline Consumer Healthcare Helps to Bridge Oral Care Gap in Appalachia
2. Activplant Corporation Announces Global Agreement with GlaxoSmithKline
3. GlaxoSmithKline and Genmab Submit Arzerra(TM) (Ofatumumab) Application to FDA for the Treatment of Advanced Stage Blood Cancer
4. GlaxoSmithKlines Drug Will Become New Clinical Gold Standard by 2012 for the Treatment of Relapsed/Refractory CLL
5. GlaxoSmithKline Awards Ten Area Healthcare Nonprofits with $40,000 Each in Funding
6. GlaxoSmithKline and Dynavax Announce Worldwide Strategic Alliance : – Developing First-in-Class Endosomal TLR Inhibitors for Autoimmune and Inflammatory Diseases –
7. GlaxoSmithKline Statement on FDA Advisory Committee Vote on Use of Asthma Medicines Containing Long-Acting Beta-Agonists
8. GlaxoSmithKline and The Carter Center Reaffirm Commitment to Global Public Health with Expansion of LF Program
9. GlaxoSmithKline to Acquire the Leading Dry Mouth Brand, Biotene
10. AUDIO from Medialink and GlaxoSmithKline: Give Kids A Boost For Their Health!
11. GlaxoSmithKline Acquires Sirtris Pharmaceuticals, Inc., a World Leader in Sirtuin Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Colorado (PRWEB) February 26, 2015 As ... millions are looking for deeper meaning, more substantial roles ... question – how do I live a life that ... 10th round of Younger Next Year Total Immersion ... revealed. This program boasts unbelievable results and jump-starts a ...
(Date:2/26/2015)... 2015 “In the last few years, ... evolution of one of the newest hair restoration technologies ... offers a machinery that facilitates the extraction of ... scalp,” said Dr. Parsa Mohebi. , Although ARTAS had ... at which the device extracted these grafts could not ...
(Date:2/26/2015)... Los Angeles, CA (PRWEB) February 26, 2015 ... to live stream his hair transplant contest winner’s ... and preparation, the winner Marc R., is all set to ... transplant using the ARTAS system. His procedure will be done ... Parsa Mohebi website. To watch the surgery, go to the ...
(Date:2/26/2015)... Thousands of people in local communities nationwide ... for the Muscular Dystrophy Association during the 2015 MDA ... that will help save and improve the lives of ... Walk events unite and rally communities to raise funds ... are compromised — including everyday abilities like walking, running, ...
(Date:2/26/2015)... February 26, 2015 PartnerTech Inc . ... & Makers Awards finalist. , The Movers ... involved in the manufacturing, processing, or distribution of tangible products ... Center. This annual event serves as Georgia’s largest local ... expected to draw more than 300 local industry and business ...
Breaking Medicine News(10 mins):Health News:The Aspen Club on Actively Aging: Telling a New Story on Aging 2Health News:Newest Technology now Available at Parsa Mohebi Hair Restoration 2Health News:Hair Transplant Contest Winner’s Surgery to be Streamed LIVE 2Health News:MDA Kicks-Off Annual Muscle Walk Season in Local Communities Nationwide to Fight Back Against Muscle Disease 2Health News:MDA Kicks-Off Annual Muscle Walk Season in Local Communities Nationwide to Fight Back Against Muscle Disease 3Health News:PartnerTech Named a Finalist for Gwinnett County Chamber of Commerce 2015 Movers & Makers Award 2Health News:PartnerTech Named a Finalist for Gwinnett County Chamber of Commerce 2015 Movers & Makers Award 3
... ordering chest CT examinations translates into positive examinations three-quarters ... study, conducted at Massachusetts General Hospital in Boston, of ... a decision support system, found that 76% of patients ... "Rising concerns about radiation risks, imaging growth and reimbursement ...
... A new analysis suggests the benefits of mammography screening ... 40 to 49 who are at an increased risk of ... out of every five American women. The researchers also ... to film mammography. These findings, with contributions from three national ...
... State University researchers have invented a protein purifier that ... The details of the invention, which appear in a ... that MSU chemists Merlin Bruening and Greg Baker,s high-performance ... step in the development of some new drugs. ...
... Dotinga HealthDay Reporter , MONDAY, April 30 (HealthDay ... a commonly used insecticide to unusual changes in the brain ... that the pesticide is at fault. The findings ... as chlorpyrifos, which is used to treat farm products in ...
... officer calling for backup while also keeping a strong hold ... a two-tier approach to fighting off a threat, new research ... the first time, the scientists managed to capture that reaction ... model of virus-infected brain cells, while also sending signals to ...
... Control and Prevention (CDC) found that one-third of U.S. adults ... depression. According to findings that appear today in Arthritis ... behalf of the American College of Rheumatology (ACR), anxiety is ... despite more clinical focus on the latter mental health condition. ...
Cached Medicine News:Health News:Research examines when benefits of screening mammography outweigh the harms for women in their 40s 2Health News:Research examines when benefits of screening mammography outweigh the harms for women in their 40s 3Health News:MSU invention could help pharmaceutical industry save money 2Health News:Insecticide Linked to Brain Abnormalities in Kids 2Health News:Insecticide Linked to Brain Abnormalities in Kids 3Health News:How does the immune system fight off threats to the brain? New research yields fresh insight 2Health News:How does the immune system fight off threats to the brain? New research yields fresh insight 3Health News:One-third of adult Americans with arthritis battle anxiety or depression 2
(Date:2/26/2015)... , Feb. 26, 2015  Lyric Pharmaceuticals Inc. today ... round totaling $20.4 million. The financing, co-led by RiverVest ... participation by Aperture Venture Partners. Lyric ... David Wurtman , M.D., M.B.A., President & Chief ... Chief Medical Officer.  In 2014, Lyric closed a seed ...
(Date:2/26/2015)... BOSTON , Feb. 26, 2015 ... ("Columbia" or "the Company"), a specialty pharmaceutical company ... health, plans to initiate a Phase II clinical ... in women undergoing transvaginal pipelle-directed endometrial biopsy in ... pre-Investigational New Drug ("IND") submission feedback from the ...
(Date:2/26/2015)... SALT LAKE CITY , Feb. 26, 2015 /PRNewswire/ ... it has launched a "best efforts" follow-on offering of ... unit consists of one share of Series E preferred ... Series E preferred stock will be convertible into four ... will be exercisable into one share of common stock ...
Breaking Medicine Technology:Columbia Laboratories to Initiate a Phase II Clinical Trial for COL-1077, Lidocaine Bioadhesive 10% Gel, in the Second Quarter of 2015 2Columbia Laboratories to Initiate a Phase II Clinical Trial for COL-1077, Lidocaine Bioadhesive 10% Gel, in the Second Quarter of 2015 3Great Basin Scientific, Inc. Announces Commencement of Public Offering 2Great Basin Scientific, Inc. Announces Commencement of Public Offering 3
... 23 Lixte,Biotechnology Holdings (OTC Bulletin Board: LIXT) ... Zhuang of the Surgical Neurology Branch (SNB),National Institute ... Health (NIH) and its collaborator, Lixte Biotechnology,Holdings. Inc., ... Association,of Cancer Research that its lead compound LB-1, ...
... First Registration Study of an Investigational Drug for Duchenne/Becker ... ... PTC Therapeutics, Inc.,(PTC), today announced the initiation of an international pivotal ... nonsense mutation. The primary objective of this registration-directed,Phase 2b trial is ...
Cached Medicine Technology:Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research 2Lixte Biotechnology Holdings Announces That Anti-Cancer Activity Against Glioblastoma in an Animal Model Was Reported at the Annual Meeting of the American Association of Cancer Research 3PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 2PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 3PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 4PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy 5
... a range of Milli-Q ultrapure water ... quality requirements. Each of the five ... specifically target contaminants detrimental to particular ... and ICP-MS. The systems incorporate a ...
... developed a range of Milli-Q ultrapure ... water quality requirements. Each of the ... to specifically target contaminants detrimental to ... biology and ICP-MS. The systems incorporate ...
... assembly allows internal or external ... coil allows rapid cool-down between ... approximately 10 C of ambient, ... only 5.7 inches wideideal for ...
Inquire...
Medicine Products: